Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Coudoin, Sylvie
FTD-GRN, NCT04408625 / 2019-003159-12: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations	Recruiting	1/2	30	Europe, US, RoW	LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone	Prevail Therapeutics, Eli Lilly and Company	Frontotemporal Dementia	08/29	08/29
Schildermans, Carine
FTD-GRN, NCT04408625 / 2019-003159-12: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations	Recruiting	1/2	30	Europe, US, RoW	LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone	Prevail Therapeutics, Eli Lilly and Company	Frontotemporal Dementia	08/29	08/29
Pelat, Julie
FTD-GRN, NCT04408625 / 2019-003159-12: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations	Recruiting	1/2	30	Europe, US, RoW	LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone	Prevail Therapeutics, Eli Lilly and Company	Frontotemporal Dementia	08/29	08/29
Capdevila, Beatriz Bosch
FTD-GRN, NCT04408625 / 2019-003159-12: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations	Recruiting	1/2	30	Europe, US, RoW	LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone	Prevail Therapeutics, Eli Lilly and Company	Frontotemporal Dementia	08/29	08/29